ID   BV-173/E255K
AC   CVCL_5K95
SY   BV173/E255K
DR   cancercelllines; CVCL_5K95
DR   Kerafast; EVC001
DR   Wikidata; Q54798655
RX   PubMed=21474579;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; STI571).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 13 fused to ABL1 exon 2 (b2a2 transcript) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 76; ABL1; Simple; p.Glu255Lys (c.763G>A); ClinVar=VCV000376090; Zygosity=Unspecified (PubMed=21474579).
CC   Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gln4045Ter (c.12133C>T); Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0181 ! BV-173
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 02-05-24; Version: 17
//
RX   PubMed=21474579; DOI=10.1158/1078-0432.CCR-11-0234;
RA   Nguyen T., Dai Y., Attkisson E., Kramer L., Jordan N., Nguyen N.,
RA   Kolluri N., Muschen M., Grant S.;
RT   "HDAC inhibitors potentiate the activity of the BCR/ABL kinase
RT   inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+
RT   leukemia cells in vitro and in vivo.";
RL   Clin. Cancer Res. 17:3219-3232(2011).
//